Clinical trial NCT01678690: An Exploratory Study of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors
Official title: An Open-Label, Exploratory, Limited Dose Escalation Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Malignant Tumors
Lead sponsor: InnoPharmax Inc.
Sponsor class: INDUSTRY
First posted: 2012-09-05
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: Open-label, Phase 0, dose-escalation study of 3 successive cohorts (3 subjects per cohort), to determine and characterize the plasma PK of gemcitabine HCl oral formulation (D07001-F4) administered once on Day 1 with 7 Days of study follow-up. In addition, oral tolerability and safety will also be assessed during this 1-week period.


Eligibility criteria: Inclusion Criteria:

1. Male or female subjects aged 18 years and older.
2. Signed and dated informed consent form.
3. Subjects with malignancies with histological or pathologic confirmation and who are clinically stable.
4. History of treatment with at least 1 cytotoxic chemotherapy regimen for the current malignancy.
5. If the subject has received cytotoxic chemotherapy within the past 14 days, the subject is beyond the nadir of white blood cell and platelet counts.
6. At least 28 days have elapsed since the subject's prior radiotherapy or any major surgery (excluding diagnostic biopsy or venous access device placement).
7. World Health Organization (WHO) performance status 0 to 2
8. Subject has an ANC ≥1500 cells/mm³, platelet count ≥ 100,000 cells/mm³, and hemoglobin ≥ 9 g/dL.
9. Subject has adequate liver function demonstrated by transaminases within normal limits (aspartate transaminase and alanine transaminase), total bilirubin ≤ 1.5 mg/dL (unless due to Gilbert's syndrome), albumin ≥ 2.5 g/dL, international normalized ratio \[INR\] \< 1.5).
10. Subject has adequate renal function: serum creatinine ≤ 1.5 x upper limit of normal.
11. Subject has a life expectancy \>24 weeks.
12. If a women of child-bearing potential, subject has a negative pregnancy test and is not breast-feeding.
13. If a women of child-bearing potential, subject is using a medically acceptable form of birth control prior to screening and for the duration of their study participation and for 1 month after the end of the study.
14. Subject is willing to comply with protocol-required visit schedule and visit requirements and provide written informed consent.

Exclusion Criteria:

1. Subject has rapidly progressive disease or rapid clinical deterioration as assessed by the Investigator.
2. Subject is receiving full-dose (therapeutic) anticoagulation therapy.
3. Subject is receiving concomitant radiotherapy.
4. Subject is intolerant or allergic or has a known hypersensitivity to gemcitabine.
5. Subject has clinically significant cardiovascular disease (for example: uncontrolled hypertension, unstable angina, congestive heart failure, or New York Heart Association Grade 2 or greater).
6. Subject has uncontrolled serious cardiac arrhythmia.
7. Subject has known active brain metastases, or any leptomeningeal metastases.
8. Subject has a history of drug or alcohol abuse within last year.
9. Subject has documented cerebrovascular disease.
10. Subject has a seizure disorder not controlled on medication.
11. Subject received an investigational agent within 30 days of screening.
12. Subject received systemic treatment for infection within 14 days of screening.
13. Subject has known human immunodeficiency virus infection or viral hepatitis.
14. Subject has any other serious medical condition that, in the investigator's medical opinion, would preclude safe participation in a clinical trial.
15. Subject has gastrointestinal disease or prior gastrointestinal surgery that may interfere with adequate oral therapy absorption.

Primary outcomes:
measure: gemcitabine (dFdC) and difluorodeoxyuridine (dFdU) plasma concentration and gemcitabine triphosphate (dFdCTP) concentration in PBMC
timeFrame: Day 1-5
Secondary outcomes:
measure: the proportion of subjects experiencing adverse events all grades, change from baseline in clinical laboratory test results, vital sign measurements, and physical examination findings
timeFrame: Day 1-8 (+/- 1) days
Other outcomes:
Locations:
city: Augusta
country: United States
facility: Georgia Regents University- Cancer Center
state: Georgia
city: Canton
country: United States
facility: Gabrail Cancer Center Research
state: Ohio
city: Dover
country: United States
facility: Gabrail Cancer Center Research
state: Ohio
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: Gabrail Cancer Center Research
name: Nashat Y. Gabrail, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Augusta University
name: Sharad Ghamande, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: National Taiwan University Hospital
name: Chia-Chi Lin, MD
role: PRINCIPAL_INVESTIGATOR
References: